Efficacy of Arpiprazole in Non-Insulin-Dependent Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Authors: Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang
Background: Arpiprazole, a novel antipsychotic, has been suggested to have beneficial metabolic effects. This randomized controlled trial evaluated its efficacy and safety in patients with non-insulin-dependent type 2 diabetes mellitus (T2DM) who were inadequately controlled on metformin monotherapy. Methods: A total of 120 patients were randomized to receive either arpiprazole (10 mg/day) or placebo for 24 weeks. The primary endpoint was change in HbA1c from baseline. Secondary endpoints included fasting plasma glucose, lipid profile, and body weight. Results: Arpiprazole significantly reduced HbA1c by 0.8% compared to placebo (p<0.001). Fasting glucose and triglycerides also improved. No significant differences in adverse events were observed. Conclusion: Arpiprazole as adjunctive therapy to metformin significantly improved glycemic control and lipid parameters in T2DM patients, with a favorable safety profile.
